Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023)
Gilead Sciences' (GILD) quarterly Income from Non-Controlling Interests came in at -$12.0 million in Q4 2023, down 71.43% YoY from -$42.0 million in Q4 2022, and down 50.0% on a QoQ basis from -$8.0 million in Q3 2023.
Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023) Analysis & Trends
Gilead Sciences (GILD) has 15 years of Income from Non-Controlling Interests data on file, last reported at -$12.0 million in Q4 2023.
- Quarterly Income from Non-Controlling Interests fell 71.43% year-over-year to -$12.0 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$12.0 million (up 74.47% YoY) and the FY2023 annual result came in at -$52.0 million, down 100.0% from the prior year.
- Income from Non-Controlling Interests declined to -$12.0 million in Q4 2023, from -$8.0 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$3.0 million in Q3 2019 to a low of -$26.0 million in Q1 2023.
- A 5-year average of -$7.9 million and a median of -$7.0 million in 2019 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2019 — Income from Non-Controlling Interests plunged 800.0% — and 2022, when it jumped 50.0%.
- Tracing GILD's Income from Non-Controlling Interests over 5 years: stood at -$7.0 million in 2019, then changed by 0.0% to -$7.0 million in 2020, then increased by 14.29% to -$6.0 million in 2021, then fell by 16.67% to -$7.0 million in 2022, then sank by 71.43% to -$12.0 million in 2023.
- The last three Income from Non-Controlling Interests figures came in at -$12.0 million (Q4 2023), -$8.0 million (Q3 2023), and -$6.0 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 10.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 741.95 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 39.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -12.00 Mn |
| Sep 30, 2023 | -8.00 Mn |
| Jun 30, 2023 | -6.00 Mn |
| Mar 31, 2023 | -26.00 Mn |
| Dec 31, 2022 | -7.00 Mn |
| Sep 30, 2022 | -3.00 Mn |
| Jun 30, 2022 | -9.00 Mn |
| Mar 31, 2022 | -7.00 Mn |
| Dec 31, 2021 | -6.00 Mn |
| Sep 30, 2021 | -6.00 Mn |
| Jun 30, 2021 | -5.00 Mn |
| Mar 31, 2021 | -7.00 Mn |
| Dec 31, 2020 | -7.00 Mn |
| Sep 30, 2020 | -7.00 Mn |
| Jun 30, 2020 | -7.00 Mn |
| Mar 31, 2020 | -13.00 Mn |
| Dec 31, 2019 | -7.00 Mn |
| Sep 30, 2019 | -3.00 Mn |
| Jun 30, 2019 | -5.00 Mn |
| Mar 31, 2019 | -7.00 Mn |